Short-course therapy with amoxycillin-clarithormycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 5, 1997, Pages 943-952

  Wurzer, H ^a,m   Rodrigo, L ^b   Stamler, D ^c   Archambault, A ^d   Rokkas, T ^e   Skandalis, N ^f   Fedorak, R ^g   Bazzoli, F ^h   Hentschel, E ⁱ   Mora, P ^j   Archimandritis, A ^k   Megraud, F ^l  

^a UNIVERSITY OF GRAZ   (Austria)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c ABBOTT LABORATORIES   (United States)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^f IASO GENERAL HOSPITAL   (Greece)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ HANUSCH HOSPITAL   (Austria)

^j HOSPITAL SEVERO OCHOA   (Spain)

^k UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^l HÔPITAL PELLEGRIN   (France)

^m MEDICAL UNIVERSITY OF GRAZ   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTACID AGENT; CLARITHROMYCIN; OMEPRAZOLE;

ABDOMINAL PAIN; ADULT; AMBLYOPIA; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; BIOPSY; BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPY; FEMALE; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; ULCER HEALING;

EID: 9844242124     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00223.x     Document Type: Article

References (64)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 7: 1311-5.
2. Axon A. Heliobacter pylori infection. J Antimicrob Chemother 1993; 32(Suppl. A): 61-8.
3. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective, double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2: 1437-42.
4. Borody T, Noonan S, Cole P, et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication, Med J Australia 1989; 151: 431-5.
5. Tytgat GNJ, Noach LA, Rauws EAJ. Helicobacter pylori infection and duodenal ulcer disease. Gastroenterol Clin N Am 1993; 22: 127-39.
6. DeCross A, Marshall B. The role of Helicobacter pylori in acid-peptic disease. Am J Med Sci 1993; 306: 381-92.
7. Heatley R. The treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1992; 6: 291-303.
8. 2-receptor antagonists for peptic ulcer disease. Aliment Pharmacol Ther 1992; 6: 3-29.
9. Rauws EAJ. Role of Helicobacter pylori in duodenal ulcer. Drugs 1992; 44: 921-7.
10. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. New Engl J Med 1993; 328: 308-12.
11. Coghlan J, Gilllgan D, Humphries H, et al. Campylobacter pylori and recurrence of duodenal ulcers: a 12-month follow-up study. Lancet 1987; 2: 1109-11.
12. Logan RPH, Bardhan KD, Celestin LR, et al. Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. Aliment Pharmacol Ther 1995; 9: 417-23.
13. Tytgat GNJ. Review article: treatments that impact favourably upon the eradication of Helicobacter and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359-68.
14. Labenz J, O'Morain C. The year in H. pylori - 1995: Eradication. Curr Opin Gastroenterol 1995; 11(Suppl. 1): 47-51.
15. Freston JW. Helicobarter pylori infection, gastritis, peptic ulcer, and gastric cancer: a round table discussion. Infect Med 1994; 11(Suppl.): 9-11.
16. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994; 272: 65-9.
17. Bell GD. Conference report: duodenal ulcer trials reported at the European Helicobacter pylori study group, Edinburgh 1995. Aliment Pharmacol Ther 1996; 10: 49-54.
18. Graham DY, Lew GM, Malaty HM. et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-6.
19. Rauws EAJ. Reasons for failure of Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 1993; 5(Suppl. 2): S92-5.
20. Cutler A, Shubert T. Patients factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993; 88: 505-9.
21. Thijs JC, Van Zwei A, et al. Efficacy and side effects of a triple-drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993; 28: 934-8.
22. Sung JY, Ling TKW, Suen R, Leung VKS, Ng EKW, Chung SCS. Amoxicillin plus omeprazole vs. triple therapy for the eradication of H. pylori and healing of duodenal ulcers. Gut 1995; 37(Suppl. 1): A6(Abstract).
23. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990; 335: 1233-5.
24. Cayla R, Lamouliatte H, Megraud F. Primary resistance of Helicobacter pylori strains to metronidazole and to clarithromycin in France in 1993. In: Program and Abstracts of the 10th World Congress of Gastroenterology, Los Angeles, CA. 1994: 96.
25. Logan RPH, Gummett PA, Misiewicz JJ, Karim QN, Walker MM, Baron JH. A one week eradication regimen for Helicobacter pylori. Lancet 1991; 338: 1249-52.
26. Borody T, Andrews P, Brandl S, et al. Relevance of in-vitro metronidazole resistance to H. pylori eradication and eradication failures. Gastroenterology 1993; 104: 44(Abstract).
27. Sobala GM, George R, Tompkins D, Finlay J, Manning A. Spontaneous healing of duodenal ulcers after eradication of H. pylori. Ir J Med Sci 1992; 161(Suppl. 10): 5.
28. Bell GD, Powell K, Burridge SM, et al. Experience with triple therapy anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pretreatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992; 6: 427-35.
29. Burette A, Glupczynski Y, DePrez C, Ramdani B. Two week combination therapies with tetracycline are less effective than similar regimens with amoxicillin. Acta Gastro-Enterologica Belgica 1993; 56(Suppl.): 131.
30. Bell GD, Powell KU, Burridge SM, et al. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin, and metronidazole compared with four alternative regimens. Q J Med 1993; 86: 743-50.
31. O'Morain C, Dettmer A, Rambow A, vonFritsch E, Fraser AG. Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. Helicobacter 1996; 1: 130-7.
32. Bazzoli F, Zagari RM, Fossi S, et al. Efficacy and tolerability of a short-term, low-dose triple therapy for eradication of Helicobacter pylori. Acta Gastro-Enterologica Belgica 1993; 56(Suppl.): 130.
33. Lamouliatte HC, Cayla R, Megraud F. et al. Amoxicillin-clarithromycin-omeprazole: the best therapy for Helicobacter pylori infection. Acta Gastro-Enterologica Belgica 1993; 56(Suppl.): 140.
34. Hosking SW, Ling TKW, Chung SCS, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 1994; 343: 508-10.
35. Sipponen P, Kekki M, Siurala M. The Sydney system: epidemiology and natural history of chronic gastritis. J Gastroenterol Hepatol 1991; 6: 244-51.
36. 13C-urea breath test for the detection of Helicobacter pylori. Eur J Gastroenterol Hepatol 1991; 3: 915-21.
37. Hachem CY, Clarridge JE, Reddy R, et al. Antimicrobial susceptibility testing of Helicobacter pylori: comparison of E-test, broth microdilution, and disk diffusion for ampicillin. clarithromycin. and metronidazole. Diagn Microbiol Infect Dis 1996; 24: 37-41.
38. Hardy DJ, Hanson CW, Hensey DM, Beyer JM, Fernandes PB. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J Antimicrob Chemother 1988; 22: 631-6.
39. Cederbrant G, Kahlmeter G, Schalen C, et al. Additive effect of clarithromycin combined with 14-hydroxy clarithromycin. erythromycin, amoxicillin. metronidazole or omeprazole against Helicobacter pylori. J Antimicrob Chemother 1994; 34: 1025-9.
40. Flamm RK, Beyer J, Tanaka SK, et al. Kill kinetics of antimicrobial agents against Helicobacter pylori. J Antimicrob Chemother 1996; 38: 719-25.
41. Goddard A, Logan R. One-week low-dose triple therapy: new standards for Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 1995; 7: 1-3.
42. Lind T, van Zanten SV, Unger P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH 1 Study. Helicobacter 1996; 3: 138-44.
43. Misiewicz JJ, Harris AW, Bardhan KD, et al. One week low-dose triple therapy for eradication of H. pylori: a large multicentre. randomized trial. Gut 1996; 38(Suppl. 1): W4.
44. Bazzoli F, Gullini S, Zagari RM, et al. Effect of omeprazole and clarithromycin plus tinidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. Gut 1995; 37(Suppl. 1): 45.
45. van der Hulst RWM, Keller JJ, Rauws EAJ, et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996; 1: 6-19.
46. Jaup BH, Norrby A. Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. Am J Gastroenterol 1995; 90: 943-5.
47. Schütze K, Hentschel E, Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. Z Gastroenterol 1995; 33: 651-3.
48. Xiang Z, Censini J, Bayelli PF, et al. Analysis of expression of CagA and vacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun 1995; 63: 94-8.
49. Atherton JC, Coa P, Peek RM Jr, et al. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. J Biol Chem 1995; 270: 17771-2.
50. Blaser MJ. Role of vacA and the cagA locus of Helicobacter pylori in human disease. Aliment Pharmacol Ther 1996; 10(Suppl. 1): 73-7.
51. Lehn N, Megraud F. Diagnosis of Helicobacter pylori. Curr Opin Gastroenterol 1996(Suppl. 1): 6-10.
52. 13C-urea breath test, Gastroenterol: Digestive Disease Week 1996, San Francisco, 2563(Abstract).
53. Axon A, Deltenre M, Eriksson S, et al. Guidelines for clinical trials in Helicobacter pylori infection. Gut. submitted.
54. Glupczynski Y, Langenberg W, Dankert J. et al. Results of a multicenter European survey in 1991 of metronidazole resistance in Helicobacter pylori - European study group on antibiotic susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992; 11: 777-81.
55. Shortridge D, Beyer J, Flamm RK, et al. Pretreatment susceptibility of isolates from a multicenter Argentine study to evaluate eradication of Helicobacter pylori in patients with gastritis or active duodenal ulcers. International Congress on Macrolides, Azalides, and Streptogramins 1996, Portugal.
56. Reddy R, Osata M, Gutierrez O, et al. Metronidazole resistance is high in Korea and Colombia and appears to be rapidly increasing in the U. S. Gastroenterol: Digestive Disease Week 1996, San Francisco, 3930 (Abstract).
57. Ling TKW, Cheng AFB, Sung JJY, et al. An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study. Helicobacter 1996; 1: 57-61.
58. Xia HX, Buckley M, Hyde D. et al. Effects of antibiotic resistance on clarithromycin combined triple therapy for Helicobacter pylori. Gut 1995; 37(Suppl. 1).
59. Mitchison DA. Development of streptomycin-resistant strains of tubercle bacilli in pulmonary tuberculosis. Thorax 1950; 5: 144-61.
60. An interim report of the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Br Med J 1952; 2: 735.
61. Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 1990 (Sept.): 1637-41.
62. Mitchison D. Drug resistance in mycobacteria. Br Med Bull 1984; 40: 84-90.
63. Honore N, Cole ST. Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 1994(Feb): 238-42.
64. Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996(Feb): 477-80.